Biography:Paul Lieberman
Paul M. Lieberman is an American biomedical researcher and chairperson of the Gene Expression and Regulation Program at the Ellen and Ronald Caplan Cancer Center at The Wistar Institute in Philadelphia.[1][2][3][4][5][6][7] He is also the Hilary Koprowski, M.D., endowed professor, the McNeil professor of Molecular Medicine and Translational Research, and the founding director for the Center for Chemical Biology and Translational Medicine at The Wistar Institute. Lieberman's research focuses on how viruses cause cancer and autoimmune disease, particularly the Epstein–Barr virus.
Education
He earned a BA in chemistry from Cornell University (1983) and a Ph.D. in molecular virology from Johns Hopkins School of Medicine (1989).[5]
Career and research
Lieberman and his laboratory have facilitated the development of the first annotated atlas of the Epstein-Barr virus epigenome.[8] In 2011, Lieberman received a Seeding Drug Discovery Award from Wellcome Trust for $4.7 million to develop a drug against Epstein-Barr virus-related cancers. This was the first project to receive such an award from the United Kingdom-based trust.[9] He also leads a team developing a drug to treat Epstein-Barr virus-related cancers.[1][2][3] This project received a United Kingdom-based Wellcome Trust Seeding Drug Discovery.
Lieberman previously served as the president of the International Association for Research on Epstein-Barr Virus and Associated Diseases and is an elected fellow of the American Association for the Advancement of Sciences (AAAS).[10]
Select publications
- "Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance". Cell 184 (3): 643–654.e13. February 2021. doi:10.1016/j.cell.2020.12.022. PMID 33482082.
- "Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes". PLOS Pathogens 17 (6): e1009618. June 2021. doi:10.1371/journal.ppat.1009618. PMID 34106998.
- "A multi-omics approach to Epstein-Barr virus immortalization of B-cells reveals EBNA1 chromatin pioneering activities targeting nucleotide metabolism". PLOS Pathogens 17 (1): e1009208. January 2021. doi:10.1371/journal.ppat.1009208. PMID 33497421.
- "Cryo-EM Structure and Functional Studies of EBNA1 Binding to the Family of Repeats and Dyad Symmetry Elements of Epstein-Barr Virus oriP". Journal of Virology 96 (17): e0094922. September 2022. doi:10.1128/jvi.00949-22. PMID 36037477.
- "DAXX-ATRX regulation of p53 chromatin binding and DNA damage response". Nature Communications 13 (1): 5033. August 2022. doi:10.1038/s41467-022-32680-8. PMID 36028493.
- Deng Z, Glousker G, et al., Lieberman PM, Tzfati, Y. Inherited mutations in the helicase RTEL1 cause telomere dysfunction and Hoyeraal-Hreidarsson syndrome. PNAS 2013.
- Dheekollu J, Chen HS, Kaye KM, Lieberman PM. Timeless-dependent DNA replication-coupled recombination promotes Kaposi's Sarcoma-associated herpesvirus episome maintenance and terminal repeat stability. Journal of Virology. 2013 Apr 87(7):369.
- Deng Z, Wang Z, Stong N, Plasschaert R, et al. Riethman H, and Lieberman PM. A role for CTCF and cohesion in subtelomere chromatin organization, TERRA transcription, and telomere end protection. EMBO J. 2012 Nov 31(21):4165.
- Kang H, Cho H, Sung GH, Lieberman PM. CTCF regulates Kaposi's sarcoma-associated herpesvirus latency transcription by nucleosome displacement and RNA polymerase programming. Journal of Virology 2013 Feb 87(3)1789.
- Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 2012 Aug 12(2)233.
References
- ↑ 1.0 1.1 Cesanek, Jamie (2022-01-10). "Trial Launched to Assess Safety and Efficacy of Novel Drug in Rare Type of Head and Neck Cancer". https://www.curetoday.com/view/trial-launched-to-assess-safety-and-efficacy-of-novel-drug-in-rare-type-of-head-and-neck-cancer.
- ↑ 2.0 2.1 "Cell： EV病毒潜伏感染的机制有了关键性的进展" (in zh). https://www.ebiotrade.com/newsf/2021-1/2021122172436838.htm.
- ↑ 3.0 3.1 "EBNA1-DNA交联促进复制终止—小柯机器人—科学网" (in zh). 2021-01-21. https://news.sciencenet.cn/htmlpaper/2021/1/202112217535255160960.shtm?id=60960.
- ↑ "Paul M. Lieberman, Ph.D.". Wistar Institute. http://www.wistar.org/our-science/scientists/paul-m-lieberman-phd. Retrieved 17 February 2014.
- ↑ 5.0 5.1 "Paul M. Lieberman, Ph.D.". University of Pennsylvania. http://www.med.upenn.edu/apps/faculty/index.php/g20000320/p4209099. Retrieved 17 February 2014.
- ↑ "Management". Vironika. http://www.vironika.com/Vironika/Management.html. Retrieved 17 February 2014.
- ↑ "The Wistar Institute and University of the Sciences Announce McNeil Professorship to Lead Collaborative Center". Newswise. http://www.newswise.com/articles/the-wistar-institute-and-university-of-the-sciences-announce-mcneil-professorship-to-lead-collaborative-center. Retrieved 17 February 2014.
- ↑ "Field guide to the Epstein-Barr virus charts viral paths toward cancer". ScienceDaily. https://www.sciencedaily.com/releases/2012/08/120823143747.htm. Retrieved 17 February 2014.
- ↑ "WISTAR ENTERS A $4.7 MILLION AGREEMENT TO DEVELOP DRUG AGAINST EPSTEIN-BARR VIRUS". Wistar Institute. http://www.wistar.org/wistar-today/wistar-wire/2011-12-15/wistar-receives-47-million-wellcome-trust. Retrieved 17 February 2014.
- ↑ "EBV Association Officers". Baylor College of Medicine. Archived from the original on 25 February 2014. https://web.archive.org/web/20140225232114/https://www.bcm.edu/ebvassociation/ebv-officers.htm. Retrieved 17 February 2014.
External links
- Dr. Lieberman's lab page on The Wistar Institute's website
- "Paul M. Lieberman Inventions, Patents and Patent Applications". 2021-12-22. https://patents.justia.com/inventor/paul-m-lieberman.
 |  |
